Press release
Aquigen Bio Introduces N‐Nitroso Pirfenidone EP Impurity B - A High-Purity Reference Standard for Pharmaceutical Analysis, Method Validation, and Regulatory Compliance in Pirfenidone Impurity Profiling
Pune-/Delran- Aquigen Bio is pleased to announce the introduction of N‐Nitroso Pirfenidone EP Impurity B, a premium reference standard designed for the highest rigor in pharmaceutical analysis and regulatory compliance. Available via custom‐synthesis, this product serves as an essential resource for analytical method development (AMD), method validation (AMV), quality control (QC), and support for Abbreviated New Drug Applications (ANDA)https://aquigenbio.com/product/n-nitroso-pirfenidone-ep-impurity-b/
Product Highlights
Name: N‐Nitroso Pirfenidone EP Impurity B
Catalog No: AQ‐N000968
CAS No: 2512237‐43‐1
Molecular Formula: C6H6N2O2
Molecular Weight: 138.1
Chemical Name: 5‐methyl‐1‐nitrosopyridin‐2(1H)‐one
Availability: Custom synthesis, ready to dispatch within 24 hours (backorder)
Application: Ideal analytical standard with traceability to pharmacopeial references (USP/EP), used in regulatory submissions and lab QC processes.
Why This Matters
Analytical precision has never been more critical. Regulatory agencies demand exact identification and quantification of impurities-especially nitrosamines, classed as potentially carcinogenic. N‐Nitroso Pirfenidone EP Impurity B delivers:
Confidence in method validation and QC through consistent, character‐verified standards.
Compliance with global regulatory guidelines, thanks to full documentation and traceability potential.
Efficiency by offering ready availability and streamlined logistics.
Aquigen Bio underscores that this product is strictly for analytical use and not intended for human consumption.
Safety & Handling
Your safety is paramount. To ensure responsible laboratory use, Aquigen Bio provides extensive guidelines, including:
Review of the Safety Data Sheet (SDS) for crucial handling instructions.
Use of appropriate Personal Protective Equipment (PPE)-like gloves, goggles, respirators, and lab coats.
Conducting procedures in well‐ventilated areas, such as fume hoods or controlled environments.
Proper labeling and storage to avoid contamination.
Adhering to local disposal laws for hazardous chemical waste.
Providing adequate training, emergency response, and incident reporting protocols.
These practices help maintain high safety standards in labs utilizing this impurity standard.
Related Category: Pirfenidone Impurity Standards
As part of Aquigen Bio's broader Pirfenidone impurity standards collection, this product is grouped under the Impurity Standards → Pirfenidone category, which includes a wide portfolio of pharmacopoeial reference compounds Aquigen Bio. You can explore additional related products here:
Category Link: Impurity Standards - Pirfenidone- AquigenBio
https://aquigenbio.com/products/impurity-standards/pirfenidone/
Product: N‐Nitroso Pirfenidone EP Impurity A
Complementing Impurity B, Aquigen also provides N‐Nitroso Pirfenidone EP Impurity A,
offering versatility for broader analytical profiling:
Catalog No: AQ‐N000969
CAS No: 126209‐21‐0
Molecular Formula: C6H7N3O
Molecular Weight: 137.1
Chemical Name: N‐(5‐methylpyridin‐2‐yl)nitrous amide
Status: Custom‐synthesized, ready to dispatch within 24 hours (backorder)
Use Cases: AMV, QC, ANDA contexts-mirroring the dual‐application nature of Impurity B
Safety: Not for human consumption; full documentation and safety measures provided
This standard allows analytical labs to address multiple impurity forms in Pirfenidone, reinforcing method robustness and regulatory readiness.
How to Request or Order
Aquigen Bio ensures a seamless procurement experience:
Submit an RFQ (Request for Quotation) with details such as quantity (MG, GM, KG), company information, and contact details.
Explore - N‐Nitroso Pirfenidone EP Impurity A
https://aquigenbio.com/product/n-nitroso-pirfenidone-ep-impurity-a/
Benefit from complete documentation, worldwide delivery, and product accuracy assurances
Production is backed by rapid dispatch capability-despite backorder status.
Final Thoughts
In the modern pharmaceutical landscape, analytical accuracy is not optional-it's essential. With N‐Nitroso Pirfenidone EP Impurity B, Aquigen Bio supports lab professionals and regulatory teams with a high‐integrity, well‐characterized impurity standard. Combined with Impurity A, the offering delivers comprehensive support for Pirfenidone impurity profiling.
For more details, documentation, or to initiate a quotation, please visit the list of Pirfenidone impurity standards.
Contact:
Aquigen Bio Sciences
281/1, Plot No 41,
Hinjawadi - Pirangut Rd,
Kasar Amboli, Pirangut,
Pune, Maharashtra 412108
Phone: +91 7030123794
Email: bd@aquigenbio.com
Visit: www.aquigenbio.com
About Aquigen Bio Sciences
Aquigen Bio Sciences is at the forefront of pharmaceutical excellence, serving as the leading resource for Pirfenione impurity standards in India. With a strong commitment to safety, innovation, and regulatory compliance, the organization specializes in impurity profiling, synthesis, and analysis, empowering pharmaceutical manufacturers globally with premier standards. Aquigen Bio Sciences' dedication to cutting-edge research ensures it remains a trusted partner in refining quality benchmarks across the pharmaceutical landscape.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Aquigen Bio Introduces N‐Nitroso Pirfenidone EP Impurity B - A High-Purity Reference Standard for Pharmaceutical Analysis, Method Validation, and Regulatory Compliance in Pirfenidone Impurity Profiling here
News-ID: 4136527 • Views: …
More Releases from Aquigen Bio Sciences

Aquigen Bio Expands its Impurity Standards Portfolio with Malathion & Dithiodisu …
Aquigen Bio Sciences, a leading pharmaceutical impurity‐standards manufacturer based in India, continues to broaden its catalog with new high‐quality analytical reference standards. These include Malathion EP Impurity A, O,O‐Dimethyl Malathion, and Tetraethyl Dithiodisuccinate, designed to support rigorous research, validation, and regulatory compliance in agrochemical and pharmaceutical analysis.
Introducing New Additions to the Impurity Standards Line-up
https://aquigenbio.com/product/tetraethyl-dithiodisuccinate/
Malathion EP Impurity A
This compound-diethyl (2R)-2‐((methoxy(methylthio)phosphoryl)thio)succinate-offers traceability to pharmacopeial standards, such as USP or EP. It is…

Aquigen Bio Launches Justicidin Impurity Standards Category to Advance Analytica …
Aquigen Bio, a leading global provider of pharmaceutical reference materials and impurity standards, proudly announces the launch of its Justicidin Impurity Standards category-strengthening its commitment to support analytical precision and regulatory compliance in plant-derived compound analysis, especially in oncology, antimicrobial, and ethnopharmacological research.
The newly introduced product line includes:
Justicidin G
https://aquigenbio.com/product/justicidin-g/
Justicidin A
https://aquigenbio.com/product/justicidin-a/
Justicidin H
https://aquigenbio.com/product/justicidin-h/
Justicidin E
https://aquigenbio.com/product/justicidin-e/
These impurity standards are now available under the newly launched Justicidin category:
https://aquigenbio.com/products/impurity-standards/justicidin/
Why It Matters:
Justicidins…

Tizanidine Nitroso Impurity 1 - High-Purity Reference Standard for Reliable Impu …
In the highly regulated world of pharmaceutical manufacturing, impurity profiling plays a critical role in ensuring drug safety, efficacy, and regulatory compliance. Among the wide range of impurity reference standards required during API development and validation, Tizanidine Nitroso Impurity 1 stands out as a vital compound for researchers and manufacturers working on Tizanidine-based formulations.
At Aquigen Bio, we are proud to offer Tizanidine Nitroso Impurity 1, a high-purity reference standard meticulously…

Aquigen Bio Launches Comprehensive Josamycin Propionate Impurity Standards Portf …
Aquigen Bio, a leading global provider of pharmaceutical reference materials and impurity standards, proudly announces the launch of its Josamycin Propionate Impurity Standards category, reinforcing its commitment to supporting analytical precision and regulatory compliance in macrolide antibiotic research and production.
The newly introduced product line includes:
Josamycin Propionate
https://aquigenbio.com/product/josamycin-propionate/
Josamycin Propionate EP Impurity A
https://aquigenbio.com/product/josamycin-propionate-ep-impurity-a/
Josamycin Propionate EP Impurity B
https://aquigenbio.com/product/josamycin-propionate-ep-impurity-b/
These impurity standards are now available under the newly launched Josamycin Propionate category:
https://aquigenbio.com/products/impurity-standards/josamycin-propionate/
Why It Matters:
Josamycin…
More Releases for Pirfenidone
Lung Fibrosis Pipeline 2024: FDA Updates, Therapy Innovations, and Clinical Tria …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Lung Fibrosis pipeline constitutes key companies continuously working towards developing Lung Fibrosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Lung Fibrosis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Lung Fibrosis Market.
The Lung Fibrosis Pipeline…
Bronchiolitis Obliterans Syndrome Pipeline Analysis (2023) Covering Clinical Tri …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 5+ key pharma and biotech companies are working on 5+ pipeline drugs in the Bronchiolitis Obliterans Syndrome therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Bronchiolitis Obliterans Syndrome Pipeline Insight,…
Bronchiolitis Obliterans Syndrome Market to Register Incremental Growth During t …
In 2022, the total market size of Bronchiolitis Obliterans Syndrome (BOS) in the 7MM was approximately USD 58 million, which is expected to rise during the study period (2019-2032). The Bronchiolitis Obliterans Syndrome Market is set to register immense growth in the coming years owing to the increasing BOS cases in the 7MM and the launch of new therapies for BOS.
DelveInsight's "Bronchiolitis Obliterans Syndrome Market Insights, Epidemiology, and Market…
Pirfenidone Market Report- Size Analysis and Prediction by Leading Manufacturers …
The Pirfenidone Market research report highlights market insights with key trends and a breakdown of the Pirfenidone Market. In addition, it provides information about products and offerings and impact due to macroeconomics and Covid-19 impact on the Pirfenidone Market. Qualitative and quantitative insights are evaluated in the research report, and the market size, growth, and share are also included in the research report. Pirfenidone Market also offers analysis and insights…
Pirfenidone Market: Generate New Growth Opportunities by 2025 and Top Key Player …
The Pirfenidone market 2020 research report is a detailed view of market opportunity by end-user segments, product Type segments, sales channels, key countries. It also provides market credentials such as history, various development and trends, market overview, regional markets and also market competitors. The report estimates the performance of the key players by 2025.
Global Pirfenidone Market Overview:
The report provides actionable insights to improve source-to-contract cycle performance in the Global…
Esbriet (pirfenidone) Market 2020 Clinical Area Segmentation to 2030
Esbriet (pirfenidone) - Drug Insight and Market Forecast – 2030
The report will make detailed analysis mainly on in-depth research on the development environment, Market size, development trend, operation situation and future development trend of Esbriet (pirfenidone) Market on the basis of stating current situation of the industry in 2020.
This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect…